Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion (2013 - 2026)

Amphastar Pharmaceuticals' Depreciation and Depletion history runs 14 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Depreciation and Depletion rose 9.62% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $32.4 million, a 12.34% increase from a year earlier, with the FY2025 full-year figure at $31.6 million, up 12.03% from the prior year.
• Depreciation and Depletion steadied at $8.1 million in Q1 2026 per AMPH's latest filing, from $8.1 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $8.3 million in Q2 2025 and bottomed at $5.6 million in Q1 2022.
• The 5-year median for Depreciation and Depletion is $6.8 million (2024), against an average of $6.9 million.
• Across the five-year window, Depreciation and Depletion slipped 1.25% in 2022 and increased 20.01% in 2025, its largest moves.
• Year by year, Depreciation and Depletion stood at $6.2 million in 2022, then grew by 7.19% to $6.6 million in 2023, then grew by 9.19% to $7.3 million in 2024, then grew by 11.22% to $8.1 million in 2025, then advanced by 0.09% to $8.1 million in 2026.
• Per Business Quant, the three latest AMPH Depreciation and Depletion figures stand at $8.1 million (Q1 2026), $8.1 million (Q4 2025), and $7.9 million (Q3 2025).